1. Home
  2. TSAT vs LUNG Comparison

TSAT vs LUNG Comparison

Compare TSAT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSAT
  • LUNG
  • Stock Information
  • Founded
  • TSAT 1969
  • LUNG 1995
  • Country
  • TSAT Canada
  • LUNG United States
  • Employees
  • TSAT N/A
  • LUNG N/A
  • Industry
  • TSAT Metal Fabrications
  • LUNG Industrial Specialties
  • Sector
  • TSAT Industrials
  • LUNG Health Care
  • Exchange
  • TSAT Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • TSAT N/A
  • LUNG 299.3M
  • IPO Year
  • TSAT 1996
  • LUNG 2020
  • Fundamental
  • Price
  • TSAT $20.89
  • LUNG $7.77
  • Analyst Decision
  • TSAT Hold
  • LUNG Strong Buy
  • Analyst Count
  • TSAT 1
  • LUNG 7
  • Target Price
  • TSAT $9.00
  • LUNG $12.64
  • AVG Volume (30 Days)
  • TSAT 103.5K
  • LUNG 464.2K
  • Earning Date
  • TSAT 05-09-2025
  • LUNG 04-30-2025
  • Dividend Yield
  • TSAT N/A
  • LUNG N/A
  • EPS Growth
  • TSAT N/A
  • LUNG N/A
  • EPS
  • TSAT 2.55
  • LUNG N/A
  • Revenue
  • TSAT $450,756,875.00
  • LUNG $83,789,000.00
  • Revenue This Year
  • TSAT N/A
  • LUNG $17.96
  • Revenue Next Year
  • TSAT N/A
  • LUNG $18.35
  • P/E Ratio
  • TSAT $9.01
  • LUNG N/A
  • Revenue Growth
  • TSAT N/A
  • LUNG 22.01
  • 52 Week Low
  • TSAT $6.93
  • LUNG $5.46
  • 52 Week High
  • TSAT $25.38
  • LUNG $10.01
  • Technical
  • Relative Strength Index (RSI)
  • TSAT 52.65
  • LUNG 52.56
  • Support Level
  • TSAT $20.60
  • LUNG $7.65
  • Resistance Level
  • TSAT $25.38
  • LUNG $8.12
  • Average True Range (ATR)
  • TSAT 2.12
  • LUNG 0.49
  • MACD
  • TSAT 0.19
  • LUNG -0.06
  • Stochastic Oscillator
  • TSAT 54.09
  • LUNG 45.71

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: